drugset / Trial / NCT00759837

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

NCT00759837

Phase 1 Completed 27 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to assess the pharmacokinetics of bosutinib and the safety and tolerability of bosutinib in healthy subjects and subjects with liver disease.

Timeline

Start
2008-10
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule